In a patient with non‑fasting labs showing mild lymphocytosis, impaired fasting glucose, mildly elevated alanine aminotransferase (ALT), borderline high low‑density lipoprotein (LDL) cholesterol, and vitamin D deficiency, what is the clinical interpretation and recommended management?

Clinical Interpretation and Management

This patient's laboratory findings suggest early metabolic dysfunction consistent with metabolic-associated fatty liver disease (MAFLD), requiring lifestyle intervention as first-line therapy, vitamin D supplementation, annual diabetes screening, and cardiovascular risk assessment with consideration for statin therapy.

Key Laboratory Abnormalities

The constellation of findings reveals:

• Impaired fasting glucose (105 mg/dL) with normal HbA1c (5.6%)
• Mildly elevated ALT (39 IU/L) with normal AST
• Borderline high LDL-C (110 mg/dL) with elevated triglycerides (133 mg/dL)
• Vitamin D deficiency (14.7 ng/mL)
• Mild absolute lymphocytosis (4.3 × 10³/µL)

Primary Concern: Metabolic-Associated Fatty Liver Disease (MAFLD)

The combination of elevated ALT, impaired fasting glucose, and dyslipidemia strongly suggests MAFLD. The elevated ALT in the context of metabolic risk factors is the hallmark finding here 1.

Immediate Management Steps:

1. Lifestyle Modification (First-Line Therapy)

• Physical activity: Prescribe 150-300 minutes/week of moderate-intensity aerobic exercise over minimum 3 days/week, plus resistance training on at least 2 days/week 1
• Weight loss target: Even modest weight reduction (5-10% body weight) significantly improves liver fat and metabolic parameters
• Smoking cessation: If applicable, refer to cessation services given markedly increased cardiovascular mortality risk 1
• Alcohol assessment: Quantify alcohol intake (must be <30 g/day for men, <20 g/day for women to maintain NAFLD diagnosis); reassess regularly 1

2. Vitamin D Supplementation

Initiate vitamin D supplementation immediately given severe deficiency (14.7 ng/mL). Recent meta-analyses demonstrate that vitamin D supplementation in MAFLD patients significantly improves:

• Fasting glucose and insulin resistance (HOMA-IR)
• Triglycerides and HDL cholesterol
• ALT levels 2

The association between vitamin D deficiency and elevated ALT is particularly relevant in this patient 3, and vitamin D deficiency independently correlates with worse glycemic control (HbA1c), hypertriglyceridemia, and central adiposity 4.

3. Diabetes Screening Protocol

Annual HbA1c screening is mandatory for patients with NAFLD/MAFLD given their high risk for type 2 diabetes 1. The current HbA1c of 5.6% places this patient in the prediabetes range, requiring:

• Repeat HbA1c annually
• Reinforce lifestyle modifications
• Monitor for progression to diabetes (HbA1c ≥6.5% or 48 mmol/mol)

4. Cardiovascular Risk Management

Cardiovascular disease is the leading cause of death in NAFLD patients 1. The lipid panel shows:

• LDL-C 110 mg/dL (borderline high)
• Triglycerides 133 mg/dL (elevated for non-fasting)
• HDL-C 68 mg/dL (protective)

Important note: These labs were non-fasting. Non-fasting lipid profiles are acceptable for cardiovascular risk assessment, with maximal mean changes being clinically insignificant 5. For non-fasting samples, abnormal values are flagged as triglycerides ≥175 mg/dL and LDL-C ≥115 mg/dL 5.

Statin consideration: Calculate 10-year ASCVD risk score. If ≥7.5%, initiate moderate-intensity statin therapy per ACC/AHA guidelines 6. The presence of MAFLD itself is an independent cardiovascular risk factor, and many patients will qualify for statin therapy based on metabolic comorbidities 1.

Monitor blood pressure: Screen for hypertension (target <130/85 mmHg), as NAFLD confers 3-fold increased risk 1.

5. Lymphocytosis Assessment

The absolute lymphocytosis (4.3 × 10³/µL) is mild and likely reactive. In the absence of other concerning features (no immature cells, normal other cell lines), this does not require immediate hematologic workup but warrants:

• Repeat CBC in 3 months
• If persistent or progressive, consider infectious workup or hematology referral

Monitoring Schedule

• Repeat ALT/AST: Every 6 months initially to assess response to lifestyle intervention
• Repeat HbA1c: Annually for diabetes screening
• Repeat lipid panel: 3-6 months after initiating lifestyle changes (and statin if prescribed)
• Repeat vitamin D: 3 months after supplementation initiation, target ≥30 ng/mL
• Repeat CBC: 3 months to reassess lymphocytosis

Critical Pitfalls to Avoid

• Do not dismiss mildly elevated ALT: Even modest elevations in the context of metabolic syndrome warrant evaluation for MAFLD and cardiovascular risk stratification
• Do not delay vitamin D supplementation: The deficiency is severe and independently associated with worse metabolic outcomes
• Do not overlook cardiovascular risk: MAFLD patients die primarily from cardiovascular disease, not liver disease 1
• Do not assume fasting is required for lipid assessment: Non-fasting lipids are valid for risk stratification 5